Noxxon and Lilly sign licensing agreement

Under the terms of the agreement Noxxon grants Lilly an exclusive worldwide license to a novel preclinical Spiegelmer, and will use its Spiegelmer technology to identify follow-on inhibitors. Lilly will conduct all preclinical and clinical development as well as the worldwide commercialization of products.

Noxxon stands to receive an initial payment, committed research funding, and milestones for the achievement of specified R&D events. In addition, Noxxon is eligible to earn royalties on worldwide sales of products commercialized by Lilly as a result of this collaboration.

Frank Morich, CEO of Noxxon, said: “This alliance with Lilly reinforces the growing excitement about our Spiegelmer therapeutics in the pharmaceutical industry. The collaboration is an important component in implementing our strategy to rapidly advance Spiegelmers into clinical development.”